LabConnect to Expand its Tennessee Facility

April 6, 2021
Pharmaceutical Technology Editors

In the Lab eNewsletter, Pharmaceutical Technology's In the Lab eNewsletter 04-07-2021, Volume 16, Issue 4

The company plans to add 20,000 ft.2 to the site, tripling its clinical trial kit building capacity and further meeting the demand for cell and gene therapies, immuno-oncology, and other advanced therapeutics services.

LabConnect, a US-based provider of laboratory and support services for the biopharmaceutical industry, has expanded its facility in Johnson City, TN.

The company, which is known for its customized clinical trial collection kits, plans to add 20,000 ft.2 to the site, tripling its clinical trial kit building capacity and further meeting the demand for cell and gene therapies, immuno-oncology, and other advanced therapeutics services, LabConnect said in a March 16, 2021 press release.

“LabConnect’s expansion is a direct result of tremendous client response to our differentiated services and intense focus on quality and customer satisfaction,” said Tom Sellig, LabConnect’s CEO, in the press release. “The new facility, which will be operational in June, is being developed with funding from a continued partnership with the State of Tennessee. This new expansion comes after the recent expansion of LabConnect’s biorepository and sample storage facility completed in July of 2020.”

Source: LabConnect